IGM BIOSCIENCES, INC. (IGMS): Price and Financial Metrics


0.38 (+1.72%)

POWR Rating

Component Grades













Add IGMS to Watchlist
Sign Up

Industry: Biotech



in industry

IGMS Stock Price Chart Interactive Chart >

Price chart for IGMS

IGMS Price/Volume Stats

Current price $22.45 52-week high $65.08
Prev. close $22.07 52-week low $12.67
Day low $21.87 Volume 101,381
Day high $23.19 Avg. volume 568,146
50-day MA $20.75 Dividend yield N/A
200-day MA $19.37 Market Cap 954.73M


IGM Biosciences, Inc. operates as a biotechnology company which develops antibodies for the treatment of cancer. It offers IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The company was founded in 2010 and is headquartered in Mountain View, CA.

IGMS Latest News Stream

Event/Time News Detail
Loading, please wait...

IGMS Latest Social Stream

Loading social stream, please wait...

View Full IGMS Social Stream

Latest IGMS News From Around the Web

Below are the latest news stories about IGM BIOSCIENCES INC that investors may wish to consider to help them evaluate IGMS as an investment opportunity.

IGM Biosciences to Present at Three Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in three upcoming investor conferences in New York: Fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12 at 1:40 p.m. ESTFireside chat at the Baird 2022 Global Healthcare Conference on Tu

Yahoo | September 6, 2022

IGM Biosciences started at BofA Securities with a buy on IgM antibody candidates

  • BofA Securities has initiated IGM Biosciences (NASDAQ:IGMS) with a buy on advantages the company's IgM antibodies in development have over existing antibody therapies.
  • The firm has a $34 price target on shares (~79% upside based on Monday's close).
  • Analyst Geoff Meacham said that IgM antibodies could have better efficacy compared ot the IgG antibodies used in other therapeutics due to additional binding units that can strongly bind to difficult targets.
  • He noted that IGM's (

    Seeking Alpha | August 29, 2022

IGM Biosciences, Inc. (IGMS) Reports Q2 Loss, Misses Revenue Estimates

IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 7.64% and 99.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 8, 2022

IGM Biosciences Announces Second Quarter 2022 Financial Results and Provides Corporate Update

– Continued Advancement in Clinical Development of Imvotamab (IGM-2323) and IGM-8444 – – Received $150 Million Upfront Payment in Connection with Closing of Collaboration Agreement with Sanofi – MOUNTAIN VIEW, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced its financial results for the second quarter ended June 30, 2022 and provided an update on recent develo

Yahoo | August 8, 2022

IGM Biosciences, Inc. (NASDAQ:IGMS) insiders placed bullish bets worth US$2.3m in the last 12 months

In the last year, multiple insiders have substantially increased their holdings of IGM Biosciences, Inc. ( NASDAQ:IGMS...

Yahoo | July 4, 2022

Read More 'IGMS' Stories Here

IGMS Price Returns

1-mo 20.57%
3-mo 8.19%
6-mo 3.89%
1-year -62.72%
3-year 23.49%
5-year N/A
YTD -23.46%
2021 -66.78%
2020 131.37%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.5645 seconds.